Fecal microbiota transplantation for indolent T-cell lymphoproliferative disorder of gastrointestinal tract: A case report and review of literature

Table 1 Specific treatment options for patients at different times

Treatment time	Specific treatment program
January 11 through February 3, 2020	CHOPE regimen
February 26 through March 24, 2020	CHOPE regimen
April 16, 2020	CHOPE regimen
May 8 through June 5, 2020	EPOCH regimen and chidamide
July 13, 2020	GDP regimen and chidamide
August 22, 2020	Cyclophosphamide regimen
November 16 through December 13, 2020	Anti-CD30 monoclonal antibody and sintilimab regimen (2 courses)
February 5 through March 3, 2021	Sintilimab, gemcitabine + oxaliplatin, reduced dose, and chidamide regimen
April 15, 2021	Tislelizumab and lenalidomide regimen
June 17, 2021	Thalidomide with first FMT
September 16, 2021	Thalidomide with second FMT
March 30, 2022	Thalidomide with third FMT
January 11, 2024	Fourth FMT (thalidomide discontinued prior)
July 3, 2024	Fifth FMT

The cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide regimen drug composition includes cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide. The etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin regimen drug composition includes etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin. The gemcitabine, cisplatin, and prednisone regimen drug composition includes gemcitabine, cisplatin, and prednisone. CHOPE: Cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide; EPOCH: Etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin; GDP: Gemcitabine, cisplatin, and prednisone; FMT: Fecal microbiota transplantation.